-
1.发明申请公开(公告)号：US20210407640A1
公开(公告)日：2021-12-30
申请号：US17357393
申请日：2021-06-24
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
2.发明授权公开(公告)号：US12159700B2
公开(公告)日：2024-12-03
申请号：US17238092
申请日：2021-04-22
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
IPC: G16H20/00 , A61K35/13 , A61K39/00 , C12N5/0783 , C12N5/09 , G06Q10/0832 , G16H10/60 , G16H80/00
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
3.发明授权公开(公告)号：US12230378B2
公开(公告)日：2025-02-18
申请号：US17357360
申请日：2021-06-24
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
IPC: G16H20/00 , A61K35/13 , A61K39/00 , C12N5/0783 , C12N5/09 , G06Q10/0832 , G16H10/60 , G16H80/00
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
4.发明申请公开(公告)号：US20210407639A1
公开(公告)日：2021-12-30
申请号：US17357360
申请日：2021-06-24
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
5.发明授权公开(公告)号：US12230379B2
公开(公告)日：2025-02-18
申请号：US17357393
申请日：2021-06-24
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
IPC: G16H20/00 , A61K35/13 , A61K39/00 , C12N5/0783 , C12N5/09 , G06Q10/0832 , G16H10/60 , G16H80/00
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US12170134B2
公开(公告)日：2024-12-17
申请号：US17519065
申请日：2021-11-04
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
7.发明授权公开(公告)号：US11631483B2
公开(公告)日：2023-04-18
申请号：US17570195
申请日：2022-01-06
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
8.发明申请公开(公告)号：US20220122707A1
公开(公告)日：2022-04-21
申请号：US17570195
申请日：2022-01-06
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
9.发明申请公开(公告)号：US20220059202A1
公开(公告)日：2022-02-24
申请号：US17519065
申请日：2021-11-04
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
10.发明申请公开(公告)号：US20210335467A1
公开(公告)日：2021-10-28
申请号：US17238092
申请日：2021-04-22
Applicant: Iovance Biotherapeutics, Inc.
Inventor： Anne Brooks , Steve Macrides , Kristin Lanzi
Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.021 seconds)
